TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.
Ondine Biomedical Inc. has launched the ‘Light Against AMR Initiative’ in collaboration with the International Photodynamic Association, aiming to accelerate the adoption of photodisinfection technologies in underserved and emerging markets. The initiative is chaired by former Mexican President Vicente Fox, who will leverage his experience in healthcare access to combat antimicrobial resistance (AMR), a growing global health crisis. This strategic collaboration seeks to establish photodisinfection as a cost-effective, scalable alternative to antibiotics, particularly in regions with limited healthcare infrastructure, and aims to unite various stakeholders to overcome access barriers.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, with its nasal photodisinfection system approved in several countries and undergoing clinical trials in the US.
Average Trading Volume: 210,638
Technical Sentiment Signal: Buy
Current Market Cap: £56.64M
See more data about OBI stock on TipRanks’ Stock Analysis page.